Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787323 | 0.76 | PIK3CD (0.44) | TEAD1FGFR1TEAD3DCUN1D1HSD17B10 | |
| SCHEMBL20334399 | 0.69 | GPR183 (0.54) | TEAD1MEN1KMT2AGPR183JAK3 | |
| SCHEMBL23848526 | 0.68 | TEAD1 (0.36) | TEAD1KMT2AGPR183JAK3 | |
| SCHEMBL27461646 | 0.68 | GPR183 (0.40) | TEAD1KMT2ATEAD3GPR183JAK3 | |
| SCHEMBL31387583 | 0.67 | L3MBTL3 (0.51) | TEAD1TEAD3DCUN1D1BTKJAK3 | |
| SCHEMBL31387587 | 0.67 | L3MBTL3 (0.51) | TEAD1TEAD3DCUN1D1BTKJAK3 | |
| SCHEMBL21787541 | 0.67 | PIK3CD (0.39) | TEAD1BTKJAK3 | |
| SCHEMBL19229733 | 0.67 | TEAD1 (0.46) | TEAD1MEN1KMT2ATEAD3BTK | |
| SCHEMBL20322723 | 0.66 | JAK3 (0.40) | TEAD1FGFR1TEAD3DCUN1D1BTK | |
| SCHEMBL26075065 | 0.66 | TEAD1 (0.39) | TEAD1KMT2AGPR183JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | TEAD1 3585/4885FGFR1 624/4885MEN1 1490/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | TEAD1 3585/4885FGFR1 624/4885MEN1 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.